Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments

Autor: Nadia Oubaya, Laurence Le Cleach, Emilie Sbidian, Theodoros Evrenoglou, Sivem Afach

Publikováno v: Journal of Clinical Epidemiology
Journal of Clinical Epidemiology, Elsevier, 2021, 133, pp.72-79. ⟨10.1016/j.jclinepi.2021.01.013⟩
Journal of Clinical Epidemiology, 2021, 133, pp.72-79. ⟨10.1016/j.jclinepi.2021.01.013⟩

International audience; Background: The availability of effective treatments for psoriasis raises ethical questions about the use of a placebo group in therapeutic trials. We evaluated the use of the placebo over time in such trials.Methods: From tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::583eeb90dce4108b7ff3fbf7da1a0e61
https://doi.org/10.1016/j.jclinepi.2021.01.013

Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model

Autor: Filleron, Thomas, Bachelier, Marine, Mazieres, Julien, Pérol, Maurice, Meyer, Nicolas, Martin, Elodie, Mathevet, Fanny, Dauxois, Jean-Yves, Porcher, Raphaël, Delord, Jean-Pierre

Publikováno v: JAMA Network Open
JAMA Network Open, 2021, 4 (12), pp.e2139573. ⟨10.1001/jamanetworkopen.2021.39573⟩

International audience; ImportanceCompared with standard cytotoxic therapies, randomized immune checkpoint inhibitor (ICI) phase 3 trials reveal delayed benefits in terms of patient survival and/or long-term response. Such outcomes generally violate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1398::2cba5cacb81de819c5077ec65e762a0b
https://hal.science/hal-03842894/document

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

Autor: Bernard Asselain, Sébastien Thureau, Marianne Leheurteur, Bernard Dubray, Stéphane Culine, Jean-Christophe Faivre, Naïma Bonnet, Vincent Marchesi, Julia Salleron, Marie-Hélène Vieillard, Jean Trédaniel, Albert Lisbona, Lionel Perrier

Publikováno v: BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), ⟨10.1186/s12885-021-07828-2⟩
BMC Cancer, BioMed Central, 2021, 21 (1), pp.117. ⟨10.1186/s12885-021-07828-2⟩
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, 2021, 21 (1), ⟨10.1186/s12885-021-07828-2⟩

Background Stereotactic Body Radiation Therapy (SBRT) is an innovative modality based on high precision planning and delivery. Cancer with bone metastases and oligometastases are associated with an intermediate or good prognosis. We assume that prolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c8f1ddcbbe3b4d2a57a58fdfd92443
https://halshs.archives-ouvertes.fr/halshs-03428060

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Autor: B. C. de Jong, S. B. Patil, M. Atger, N. Saluhuddin, Gabriella Ferlazzo, Vivian Cox, Helen McIlleron, Lawrence Oyewusi, Elmira A. Berikova, Aamir J. Khan, S. Wasserman, Michael Rich, M. Moschioni, D. Dos Santos Tozzi, Julia Coit, C. Delifer, L. Pichon, V. Ducher, Lorenzo Trippa, M. Gouillou, Lorenzo Guglielmetti, S. Panda, K. O’Brien, Matteo Cellamare, S. Cloez, Peter Zimetbaum, Carole D. Mitnick, Leonid Lecca, P. Rupasinghe, M. Mazmanian, Elisabeth Baudin, Uzma Khan, O. Okunbor, Maryline Bonnet, E. Chang, A. N. LaHood, Patrick P. J. Phillips, Gustavo E. Velásquez, Elisa Ardizzoni, M. Tamirat, Kwonjune J. Seung, N Lachenal, J. M. Do, Francis Varaine

Publikováno v: Trials, vol 22, iss 1
Trials
Trials, BioMed Central, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Trials, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩

Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476e2049884ad266a73b1f9c63d6be18
https://escholarship.org/uc/item/7fb6h2xd

Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy

Autor: Rainer Spanagel, Maurice Dematteis, Nicolas Simon, Otto-Michael Lesch, Bo Söderpalm, François Paille, Amine Benyamina, Giovanni Addolorato, Jürgen Rehm, Henri-Jean Aubin, Wim van den Brink, Roch Poulnais, Anna E. Goudriaan, Icro Maremmani, Bruno Scherrer, Fabio Caputo, Antoni Gual, Pascal Perney, Henriette Walter, Quentin Raffaillac, Lorenzo Leggio, Wolfgang H. Sommer, David J. Nutt, Julien Guiraud, Andrea de Bejczy, Benjamin Rolland, Falk Kiefer

Publikováno v: Alcoholism: Clinical and Experimental Research
Alcoholism: Clinical and Experimental Research, Wiley, 2021, 45 (9), pp.1722-1734. ⟨10.1111/acer.14670⟩
Alcoholism: Clinical and Experimental Research, 2021, 45 (9), pp.1722-1734. ⟨10.1111/acer.14670⟩
Alcoholism, clinical and experimental research, 45(9), 1722-1734. Wiley-Blackwell

International audience; Background: There is considerable unexplained variability in alcohol abstinence rates (AR) in the placebo groups of randomized controlled trials (RCTs) for alcohol dependence (AD). This is of particular interest because placeb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2c1ccec9079b7c919a2d25df134935
https://pubmed.ncbi.nlm.nih.gov/34418121